RenovoRx Management
Management criteria checks 2/4
RenovoRx's CEO is Shaun Bagai, appointed in Jun 2014, has a tenure of 10.58 years. total yearly compensation is $939.12K, comprised of 55.4% salary and 44.6% bonuses, including company stock and options. directly owns 1.22% of the company’s shares, worth $412.48K. The average tenure of the management team and the board of directors is 2.5 years and 7.1 years respectively.
Key information
Shaun Bagai
Chief executive officer
US$939.1k
Total compensation
| CEO salary percentage | 55.4% |
| CEO tenure | 10.6yrs |
| CEO ownership | 1.2% |
| Management average tenure | 2.5yrs |
| Board average tenure | 7.1yrs |
Recent management updates
Recent updates
We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully
Oct 26
Is RenovoRx (NASDAQ:RNXT) In A Good Position To Invest In Growth?
Mar 31Companies Like RenovoRx (NASDAQ:RNXT) Could Be Quite Risky
Dec 16RenovoRx reports Q2 results
Aug 15Is RenovoRx (NASDAQ:RNXT) In A Good Position To Deliver On Growth Plans?
Aug 04RenovoRx names new finance CFO
Jul 19RenovoRx (NASDAQ:RNXT) Is In A Good Position To Deliver On Growth Plans
Mar 16We Think RenovoRx (NASDAQ:RNXT) Can Afford To Drive Business Growth
Nov 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$9m |
| Jun 30 2024 | n/a | n/a | -US$8m |
| Mar 31 2024 | n/a | n/a | -US$8m |
| Dec 31 2023 | US$939k | US$520k | -US$10m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$10m |
| Mar 31 2023 | n/a | n/a | -US$10m |
| Dec 31 2022 | US$841k | US$495k | -US$10m |
| Sep 30 2022 | n/a | n/a | -US$10m |
| Jun 30 2022 | n/a | n/a | -US$9m |
| Mar 31 2022 | n/a | n/a | -US$8m |
| Dec 31 2021 | US$988k | US$323k | -US$6m |
| Sep 30 2021 | n/a | n/a | -US$5m |
| Jun 30 2021 | n/a | n/a | -US$4m |
| Mar 31 2021 | n/a | n/a | -US$4m |
| Dec 31 2020 | US$253k | US$253k | -US$4m |
| Dec 31 2019 | US$270k | US$240k | -US$4m |
Compensation vs Market: Shaun's total compensation ($USD939.12K) is above average for companies of similar size in the US market ($USD645.47K).
Compensation vs Earnings: Shaun's compensation has increased whilst the company is unprofitable.
CEO
Shaun Bagai (47 yo)
10.6yrs
Tenure
US$939,115
Compensation
Mr. Shaun R. Bagai has been the Chief Executive Officer and Director of RenovoRx, Inc. since June 2014. He is Secretary at RenovoRx, Inc. He joined RenovoRx in June 2014 and in his first few months has bee...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.7yrs | US$507.76k | 0.20% $ 66.9k | |
| CEO, Secretary & Director | 10.6yrs | US$939.12k | 1.22% $ 412.5k | |
| Vice President of Operations and R&D | less than a year | no data | no data | |
| VP, Controller & Principal Accounting Officer | 2.5yrs | no data | 0% $ 0 | |
| Chief Clinical Officer | no data | no data | 0% $ 0 | |
| Senior VP and Head of Corporate Strategy & Partnerships | less than a year | no data | no data |
2.5yrs
Average Tenure
56yo
Average Age
Experienced Management: RNXT's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.7yrs | US$507.76k | 0.20% $ 66.9k | |
| CEO, Secretary & Director | 10.6yrs | US$939.12k | 1.22% $ 412.5k | |
| Independent Director | 12yrs | US$82.00k | 0% $ 0 | |
| Independent Director | 12.1yrs | US$77.00k | 0.14% $ 47.4k | |
| Member of Scientific Advisory Board | 1.6yrs | no data | no data | |
| Independent Director | 1.8yrs | US$173.72k | 0.17% $ 57.8k | |
| Member of Advisory Board | 7.5yrs | no data | no data | |
| Member of Advisory Board | 7.5yrs | no data | no data | |
| Independent Director | 6.3yrs | US$82.00k | 0.17% $ 57.8k | |
| Member of Scientific Advisory Board | 1.2yrs | no data | no data |
7.1yrs
Average Tenure
67.5yo
Average Age
Experienced Board: RNXT's board of directors are considered experienced (7.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/17 06:25 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
RenovoRx, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Edward Woo | Ascendiant Capital Markets LLC |
| Jason McCarthy | Maxim Group |